Results The most common indication for KRD-PACE was BMPC ≥ 10% in 16 patients (60%), followed by CPCs in 11 (41%). The median age was 61 years (range, 35- 69), and the median BMPC prior to treatment was 10% (range, 5 – 47%). The overall response rate was 43%, and a ...
【参考文献】 Leypoldt LB, Tichy D, Besemer B, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2023 Sep 27:JCO2301696. doi: 10.1200/JCO.23.01696. 责任编辑:CA-llx 内容编辑:XU 排版编辑:CA-十一 ...
参考来源: Leypoldt LB, Tichy D, Besemer B, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2024;42(1):26-37. doi:10.1200/JCO...
参考文献 Leypoldt LB, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.J Clin Oncol . 2023 Sep 27;JCO2301696. doi: 10.1200/JCO.23.01696.
VRDvsKRDforFrontlineTreatmentofMultipleMyeloma:Istheverdictin?PresentedByJesusBerdejaatTBD Myelomanumbers PresentedByJesusBerdejaatTBD MMTreatmentParadigm PresentedByJesusBerdejaatTBD ResponseDurationandAttritioninMyeloma PresentedByJesusBerdejaatTBD OverviewClinicalResponse:CombinationTx PresentedByJesusBerdejaatTBD ...
However, the authors said while those data were robust enough to lead to carfilzomib’s approval for the treatment of RRMM in the United States and Europe, there remains a relative lack of data on the safety and efficacy of real-world patients, since many patients that might face the ...
multiple myelomarelapsereal‐lifesafetyCarfilzomib–lenalidomide–dexamethasone (KRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM). We conducted a retrospective analysis of 197 RRMM patients (pts) between January 2016 and March 2018 in six Italian hematologic centers,...
Overall, 9% and 4% of patients treated with VRd and KRd, respectively, had treatment discontinuation due to AEs (P=0.22). There were no deaths in the two groups. Conclusion Using real-world evidence data, we defined the safety profiles of VRd and KRd. In sharp contrast to clinical ...
[Here,] we learned that patients who had standard-risk multiple myeloma and zero or only one high-risk cytogenetic abnormality did not have any significant progression despite not being on maintenance [treatment]. Having said that, patients who had two or more high-risk cyt...
Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial. Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma ...